Skip to content
Home page - Centenary Institute Centenary Institute

Primary menu

  • Research
        • Research

          The latest medical research into our most complex health challenges across biomedical AI, cancer, cardiovascular diseases, inflammation, immunity, age-related, rare and infectious diseases.

          Learn more

        • Biomedical AI
        • Cancer Innovations
        • Cardiovascular Research
        • Healthy Ageing
        • Infection & Immunity
        • Inflammation
        • Rare Diseases & Gene Therapy
        • Laboratories
        • Diseases
        • Expertises
        • Breakthroughs
        • Technologies
          • Clinical Translation
  • Support us
        • Support us

          By supporting the Centenary Institute you can help improve human health through excellence in medical research

          Learn more

        • Workplace giving
        • Host or join a fundraiser
        • Gift in your Will
        • Donate in Memory
        • Community and research
  • Careers & students
        • Careers & Students

          Postdoctoral and postgraduate students can work alongside world-leading medical researchers within state-of-the-art research facilities.

        • Career Opportunities
        • Student Opportunities
  • Health hub
        • Health hub

          A range of practical information to assist in the possible preventions to disease through evidence-based research on how the body works.

          Learn more

        • Inflammation
        • The Good Gut Anti-Inflammatory Diet
          • Healthy Recipes
        • Ageing
        • Exercise Snack Program
  • News & events
        • News & Events

          Explore the latest research breakthroughs and ways you can take part in our series of digital and in-person events

        • News
        • Events
        • Media Hub
          • Statements
        • Real stories
  • About us
        • About us

          We are world-leading independent medical research institute that drives collaboration to accelerate and translate solutions to our most complex health challenges

          Learn more

        • Governance
        • Corporate information
        • Annual reports
        • Our researchers
          • Animals in research
        • Contact
  • Donate
    Centenary Institute > News > New treatment offers hope for advanced liver cancer

New treatment offers hope for advanced liver cancer

Date time 26 September, 2023
News Type News type Media release
Dr Ken Liu
Researchers have discovered a new way to treat hepatocellular carcinoma (HCC), the most common type of liver cancer and the third leading cause of cancer death worldwide.

The Centenary Institute led study revealed an encouraging treatment strategy involving the use of a new drug called Blockmir CD5-2, combined with a drug called programmed cell death protein 1 antibody (anti-PD1 antibody). This combination proved effective in reducing liver tumour size in mice.

Lead author of the study, Dr Ken Liu, a researcher in the Centenary Institute’s Centre for Cancer Innovations said the discovery was exciting and had the potential to be a viable treatment for advanced liver cancer.  

“The synergistic effect of the drugs Blockmir CD5-2 and anti-PD1 antibody significantly reduced the size of liver tumours in mice in our study. We believe that this dual-drug approach enhances the immune system, rendering it more efficient in combatting cancer cells and reducing tumours,” said Dr Liu.

Dr Liu explained that liver tumours often have abnormal blood vessels and low oxygen levels, creating an environment that suppresses the immune system and the body’s ability to fight cancer.

“Blockmir CD5-2 addresses this issue by promoting the health of tumour blood vessels through the activation of a protein called VE-Cadherin. This results in improved blood supply and oxygen levels within the tumours,” said Dr Liu.

“The enhanced blood vessel conditions within the tumours means that more cancer-targeting immune cells, specifically cytotoxic T cells, can infiltrate the tumour and effectively combat the disease,” he said.

The researchers said that use of the anti-PD1 antibody was also a crucial component of the innovative treatment approach, helping the immune system fight cancer more effectively by blocking a protein that hinders the immune response.

Senior study authors, Professor Jennifer Gamble from the Centenary Institute’s Centre for Healthy Ageing and Professor Geoff McCaughan from the Centenary Institute’s Centre for Cancer Innovations said that current effective treatment options for liver cancer were limited and that the new therapeutic approach held tremendous potential for effectively treating such a challenging disease.

The research was published in the journal Frontiers in Immunology.

Publication:

Novel miRNA-based drug CD5-2 reduces liver tumour growth in diethylnitrosamine (DEN)-treated mice by normalising tumour vasculature and altering immune infiltrate.

Themes

  • Cancer Innovations

    Cancer Innovations

Media enquires

For all media and interview enquiries, please contact Alison Mendel

Phone number Phone Number +61 434 629 469

Email Email a.mendel@centenary.org.au

Media Release

New treatment offers hope for advanced liver cancer

Download

Recent Stories

  • New platform to evolve proteins for better therapies

    Researchers from the Centenary Institute, in collaboration with the University of Sydney, have developed a powerful new tool to evolve proteins directly within mammalian cells, offering a more effective way to design medical treatments tailored to the human body.
    News Type: Media release
    Date 08 May 2025
  • Turning off protein may help prevent liver cancer

    New research from the Centenary Institute has found that switching off a specific protein in liver cells may help prevent the early development of liver cancer.
    News Type: Media release
    Date 16 Apr 2025
  • Event shines spotlight on genetic heart disease in young people

    The Centenary Institute has hosted a community event, titled ‘A Needle in a Haystack: Unlocking the Secrets of Genetic Heart Conditions’. The event aimed to advance understanding of inherited heart disease and sudden cardiac death in young people.
    News Type: Community
    Date 10 Apr 2025
  • Finding answers for sudden cardiac death in young people

    Each week in Australia, up to three young people die suddenly and unexpectedly from sudden cardiac death, often due to an undiagnosed genetic heart condition. These conditions typically go unnoticed until tragedy strikes, leaving families devastated and searching for answers.
    News Type: Media release
    Date 02 Apr 2025

Subscribe to receive news on
research updates and free events

Newsletter

The Centenary Institute is a world-leading independent Medical Research Institute.

We acknowledge the Gadigal of the Eora Nation, the traditional custodians of the Country on which the Centenary Institute stands.

About

  • About
  • Governance
  • Corporate information

Research

  • Our researchers
  • News
  • Media hub

Careers & studies

  • Career opportunities
  • Life at Centenary

Links

  • Contact
  • Privacy statement

Contact us

Building 93, Royal Prince Alfred Hospital
Missenden Rd
Camperdown NSW 2050 Australia
Telephone +61 2 9565 6100
Fax +61 2 9565 6101

Contact Privacy

Centenary Institute ABN 22 654 201 090 (DGR 1) • Centenary Institute Medical Research Foundation ABN 85 778 244 012 (DGR 2)
© 2017 Centenary Institute of Cancer Medicine and Cell Biology.

  • Linkedin
  • Facebook
  • Twitter
  • Youtube
  • Instagram